# Monte Rosa Therapeutics Inc. (GLUE) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $13.84, market value $1.2 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Monte Rosa Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 41.1×**. Each dollar of revenue is priced at 41.1×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 2.4×**. The shares trade at 2.4× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -2.7%** (5-yr avg -11.8%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -633.0%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -31.2%**. The company reported a net loss over the last twelve months.
- **Return on equity: -16.6%**. Return on equity is negative because earnings are negative.
- **Return on assets: -35.9%**. Each dollar of assets produces -35.9% of profit.

## Growth
- **Revenue growth (1 yr): 63.5%**. Revenue grew 63.5% over the last year.

## Financial health
- **Current ratio: 6.12** (quick 6.12). Current assets cover the next year's liabilities 6.12 times.
- **Altman Z-score: 4.77**. A Z-score of 4.77 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Monte Rosa Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (6 analysts). 6 analysts cover Monte Rosa Therapeutics Inc.; the consensus is strong_buy, with an average price target of $28.50 (+106% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 181.9%** (YTD -11.7%, 3-mo -15.5%). The shares are up 181.9% over twelve months including dividends.
- **From 52-week high: -46.3%** (188.9% above the low). Trading 46% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 35**. An RSI of 35 is neutral.
- **Beta (1 yr): 0.99** (volatility 97%). Beta of 0.99 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=GLUE · Page: https://foliofundamentals.com/stocks/glue

Not investment advice.